Investment Rating - The investment rating for the company is upgraded to "Buy" [5] Core Views - The company is leveraging a comprehensive retail strategy to address operational challenges and diversify its customer base [5] - The company has faced short-term profit impacts due to increased discounts but maintains a leading dividend payout ratio in the industry [7] - The core international brand partnerships are gradually recovering, and new brand acquisitions are expected to enhance the company's diversified layout [7] - The company is projected to achieve a net profit of RMB 1.416 billion in FY2026, with a growth rate of 10.14% [7] Financial Performance Summary - For FY2024, the company is expected to generate revenue of RMB 27,012.90 million, reflecting a year-on-year decline of 6.64% [6] - The net profit for FY2024 is projected at RMB 1,286 million, down 41.89% year-on-year [6] - The company’s gross margin for FY2024 is estimated at 38.4%, a decrease of 3.4 percentage points compared to the previous fiscal year [7] - The company plans to maintain a total dividend payout ratio of 135% for FY2024/25, continuing to provide high dividend returns to shareholders [7] Revenue and Profit Forecast - Revenue forecasts for the company are as follows: RMB 28,933.20 million in 2024, RMB 27,012.90 million in 2025, and RMB 26,445.63 million in 2026, with respective growth rates of 6.87%, -6.64%, and -2.10% [6] - The projected net profit for the years 2026 to 2028 is RMB 1,416.34 million, RMB 1,670.93 million, and RMB 1,980.06 million, with growth rates of 10.14%, 17.98%, and 18.50% respectively [6][7]

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook on its performance and growth potential [6][9]. Core Views - The company is positioned to benefit from the expanding demand for high-performance rare earth permanent magnets, particularly driven by the growth in the electric vehicle and robotics sectors. The report highlights that the company has a competitive edge due to its scale, profitability, and technological advantages [8][11][35]. Summary by Sections 1. Demand for High-Performance Rare Earth Permanent Magnets - The demand for high-performance rare earth permanent magnets is expected to continue expanding, driven by applications in consumer electronics, variable frequency air conditioners, energy-saving elevators, industrial robots, wind power, and new energy vehicles. The global market demand for high-performance rare earth permanent magnets is projected to reach 10.3/11.4/12.9/14.2 million tons from 2024 to 2027, with a CAGR of 11% [8][15][24]. 2. Company’s Competitive Advantages - The company is recognized as a leading player in the magnetic materials sector, benefiting from scale effects, profitability, and technological advantages. Its production capacity is expected to increase from 23,000 tons in 2023 to 40,000 tons in 2025, and further to 60,000 tons by 2027. The company has also invested in a new project in Mexico to enhance its production capabilities for magnetic components [35][42][43]. 3. Profit Forecast and Valuation - The report forecasts the company's revenue to reach 87.9 billion RMB in 2025, with net profits of 5.5 billion RMB, and projects continued growth through 2027. The price-to-earnings (P/E) ratios for the company are estimated to be 50, 42, and 31 for the years 2025, 2026, and 2027, respectively [7][47][50].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a clear growth trajectory in the short, medium, and long term, with potential for both volume and price increases in gold and silver [5][9]. Core Views - The dual catalysts of "interest rate cuts" and "Trump 2.0" are expected to sustain upward momentum in gold and silver prices. In the medium term, "Trump 2.0" may become the primary driver in the gold market during a 90-day tariff pause, with expectations of tariff increases, extended tax cuts, and "stagflation" providing strong support for rising gold prices. In the long term, these dual catalysts will continue to drive prices through 2025, supported by central bank reserves amid a backdrop of protectionism and great power competition [5][57][65]. - The company is a domestic leader in silver mining, having acquired several gold mining assets, which positions it well for future growth. As of the end of 2024, the company has identified approximately 12,000 tons of silver and 34 tons of gold, with an annual mining capacity nearing 2 million tons [6][15]. Summary by Sections Market Performance - The company's closing price is 13.45 yuan, with a total market capitalization of approximately 9.28 billion yuan and a circulating market value of about 8.97 billion yuan. The debt-to-asset ratio stands at 45.60%, and the net asset value per share is 4.40 yuan [3]. Financial Projections - The company is projected to achieve revenues of 2.498 billion yuan in 2025, with a year-on-year growth rate of 24.10%. The net profit attributable to shareholders is expected to be 576 million yuan, reflecting a 47.74% increase. Earnings per share (EPS) are forecasted at 0.84 yuan [7][9]. Growth Drivers - The company has a clear growth path for production from its upcoming mines, with several projects expected to come online between 2025 and 2027. Key projects include the Honglin Mining and Yindu Mining, which are anticipated to start production in 2025 and 2026, respectively [6][36][40]. - The company is actively pursuing resource acquisitions to enhance its growth potential, with plans to complete at least one acquisition project by 2025 [11][41]. Profitability and Performance Recovery - The company experienced a significant recovery in 2024, with a net profit of 390 million yuan, a 163.56% increase year-on-year, driven by the completion of technical upgrades at its subsidiaries and rising base metal prices. The first quarter of 2025 showed a revenue increase of 33.92% year-on-year [43][44]. Resource and Production Capacity - The company has a robust resource base with high-grade deposits, particularly in the Daxinganling region, which supports its strong profitability. The ongoing construction of new mines is expected to further enhance production capacity [27][30][33].

hyzqdatemark 2025 年 05 月 22 日 政策发力，经济稳增向好 ——2025 年 4 月经济数据点评 投资要点： 证券分析师 廖志明 SAC：S1350524100002 liaozhiming@huayuanstock.com 证券研究报告 固收定期报告 请务必仔细阅读正文之后的评级说明和重要声明 4 月消费改善。4 月社会消费品零售总额 3.7 万亿元，同比增长 5.1%，环比增长 0.2%。 4 月升级类商品与绿色消费成为核心驱动力，金银珠宝、体育娱乐用品、家用电器、 家具分别同比+25.3%/+23.3%/+38.8%/+26.9%。1-4 月服务零售额同比增长 5.1%。 联系人 投资增速略微放缓。1-4 月全国固定资产投资（不含农户）14.7 万亿元，同比增长 4.0%，增速较 1-3 月份放缓 0.2pct。前四个月全国基础设施投资同比增长 5.8%， 制造业投资同比增速达 8.8%。房地产行业整体仍承压，但结构性改善信号显现，1-4 月新建商品房销售面积同比降幅较一季度收窄 0.2pct 至 2.8%。 4 月出口数据展现出较强韧性，在复杂国际环境中实现超预期增长。4 月在 ...

建筑材料 行业专题报告 hyzqdatemark 2025 年 05 月 22 日 戴铭余 SAC：S1350524060003 daimingyu@huayuanstock.com 王彬鹏 SAC：S1350524090001 wangbinpeng@huayuanstock.com 郦悦轩 SAC：S1350524080001 liyuexuan@huayuanstock.com 朱芸 SAC：S1350524070001 zhuyun@huayuanstock.com 证券研究报告 唐志玮 tangzhiwei@huayuanstock.com 板块表现： 由单边下行走向结构分化，赛道及龙头α开始显现 投资评级： 看好（维持） ——建材行业 2024 年报及 2025 年一季报综述 投资要点： 风险提示：经济恢复不及预期，化债力度不及预期，房地产政策不及预期 请务必仔细阅读正文之后的评级说明和重要声明 | 1. 综述:行业压力仍存,结构性拐点逐步显现…………………………………………………………………………………… 5 | | --- | | 2. 消费建材:行业逐步探底,结构分化开始显现. | | 3. ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [5][9]. Core Views - The company is recognized as a national-level "little giant" in precision injection molded parts, with expected capacity release in 2026 to support new products and expansion into new fields [5]. - The company has made a strategic investment in Moxun Technology, which focuses on the development and manufacturing of brushless motors and automotive actuators, enhancing production capabilities and synergies [6]. - The company has established strong relationships with leading automotive brands, including BYD, Huawei, and Tesla, and has seen significant growth in its new energy vehicle parts business, which accounted for 30% of sales in 2024 [6][9]. Financial Performance - In 2024, the company is projected to achieve revenue of 286 million yuan, a year-on-year increase of 23.63%, and a net profit of 63 million yuan, reflecting a growth of 56.86% [8]. - The company’s revenue and net profit forecasts for 2025 are 364 million yuan and 80 million yuan, respectively, with corresponding growth rates of 27.21% and 28.47% [9]. - The earnings per share (EPS) are expected to increase from 0.94 yuan in 2024 to 1.21 yuan in 2025, indicating a positive growth trajectory [9]. Market Position and Strategy - The company is a leader in the domestic market for precision injection molded parts, with a market share increase from 25% to 30% for key products like wiper motor gears [6]. - The company is actively expanding its international market presence, with exports to countries such as France, Mexico, and Germany, achieving export revenue of 38.36 million yuan in 2024 [6]. - The company is committed to digital transformation and smart manufacturing, having established intelligent production workshops and implemented advanced manufacturing technologies [6].

证券研究报告 晨会 hyzqdatemark 2025 年 05 月 21 日 投资要点： 资料来源：聚源，华源证券研究所，截至2025年05月21日 华源晨会精粹 20250521 固定收益 "科创债"新政首周，有何特征？——信用债热点事件系列：科创债新政 后首周，银行是科创债发行的绝对主力，且银行以国股大行为主。从首周的发行情 况来看，科创债的发行主体明显呈现高评级、央国企的特征。从资金用途的变化来 看，本次"科创债"新政放宽了对科创债募集资金用途的限制。目前，已发行的科 创债所创设的创新条款主要包括转股选择权、超额增发权等，也有信用增进机构为 部分已发行科创债创设了信用风险缓释凭证（CRMW）。我们认为，在当前政策支 持和市场高关注度的背景之下，叠加科创债相关政策和发行条款的多元化创新，短 期内科创债的信用风险整体较低。目前科创债发行整体尚未放量，尤其是股权投资 机构科创债目前发行规模整体不大，建议选择资质良好的发行主体，并关注其科创 债一级发行的投标机会。结构上来看，建议择优关注设置了转股选择权、票面利率 挂钩等创新条款，或由第三方增信机构创设了相应信用风险缓释凭证的科创债，博 弈科创债上市初期流动性 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights a significant overseas licensing deal for the PD1/VEGF dual antibody with Pfizer, exceeding market expectations with a transaction scale of over $1.25 billion upfront payment and potential milestone payments of up to $4.8 billion, along with a double-digit percentage sales share [7] - The company is expected to show substantial revenue growth, with projected revenues reaching RMB 19.1 billion in 2025, representing a year-on-year growth rate of 109.7% [6][8] - The report anticipates a dramatic increase in net profit, forecasting RMB 9.8 billion in 2025, a year-on-year increase of 368.2% [6][8] - The company is expected to maintain a strong market position with core products like Teibiao and Mandi showing robust growth, with Teibiao's sales projected at RMB 5.06 billion in 2024, a 20.4% increase [7] - The report suggests that the company's innovative products and partnerships with various pharmaceutical companies will provide additional revenue growth opportunities [7] Financial Summary - The company's projected operating income for 2025 is RMB 19,102 million, with a gross profit margin of 86.5% [8] - The estimated earnings per share for 2025 is RMB 4.08, with a projected price-to-earnings ratio of 4.37 [6][8] - The report estimates a target market value of approximately RMB 595 billion, equivalent to about HKD 645 billion, based on the company's stable growth and the high elasticity provided by innovative products [7]

Investment Rating - The report gives an initial investment rating of "Buy" for the company [4][9]. Core Views - The core investment logic suggests that the impact of centralized procurement on existing formulations is gradually clearing, and with a continuously enriched product matrix and structural upgrades, the company's performance is expected to return to a growth trajectory. Additionally, the exploration of diversified innovative models opens up new possibilities [5][11]. Summary by Relevant Sections Company Overview - Founded in 2001, the company has over 20 years of experience in the pharmaceutical field, focusing on the R&D, production, and sales of chemical drug formulations, chemical raw materials, and traditional Chinese medicine formulations. The company was successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2021 [15]. Market Performance - The company aims to expand its high-end pharmaceutical industrialization platform with an "integrated raw material and formulation" advantage, solidifying its generic drug segment. The formulation products are the core contributors to the company's revenue, with significant contributions from the digestive, respiratory, and anti-infection sectors [6][38]. Key Products and Innovations - The antidepressant ZG001 is expected to become a new generation of fast-acting, non-addictive, oral antidepressants, which could revolutionize the treatment landscape for depression. The global antidepressant market is projected to reach $17.6 billion by 2030 [7]. - The company is also advancing research on endangered animal material substitutes, with the ZY-022 project set to progress to clinical trials in 2025 [8]. Financial Forecasts - The company is projected to achieve net profits of 178 million, 196 million, and 218 million yuan from 2025 to 2027, with year-on-year growth rates of 8.6%, 9.6%, and 11.3%, respectively. The current stock price corresponds to P/E ratios of 24, 21, and 19 times for the respective years [9][24]. Strategic Initiatives - The company has launched its first round of equity incentives in early 2025, which is expected to invigorate new development momentum. The incentive plan aims for revenue growth of no less than 10% and 20% for 2025 and 2026, respectively [22][11]. Research and Development - The company is continuously increasing its R&D investment, with a projected R&D expense ratio of 11.2% in 2024, reflecting a 4.0 percentage point increase year-on-year. This is primarily due to increased investment in R&D projects [28][30]. Competitive Landscape - The company maintains a strong domestic market position, with over 70% market share for its leading products, such as Entecavir. The integration of raw materials and formulations enhances its competitive edge in the market [35][36]. Product Pipeline - The company has a robust pipeline with 56 chemical drug formulation approvals and 19 traditional Chinese medicine formulation approvals as of the 2024 report date. The company plans to submit 21 generic drug registration applications in 2025 [45][46].

Investment Rating - The report assigns an "Accumulate" rating for the company, indicating a positive outlook based on its growth potential in the precision motion control solutions sector [5]. Core Insights - The company specializes in customized precision motion control solutions, benefiting from the anticipated acceleration of the humanoid robot industry. In Q1 2025, the company's net profit attributable to shareholders increased by 136% year-on-year [5]. - The company has established a long-term strategic partnership with Mindray Medical, focusing on domestic substitution in the medical equipment sector, which is supported by favorable policies [5]. - The humanoid robot sector is seeing active product platform development, with the company making significant advancements in core technologies [5][6]. Financial Performance - In 2024, the company is projected to achieve revenue of 224 million yuan, with a net profit of 39 million yuan. For Q1 2025, revenue reached 59 million yuan, reflecting a year-on-year growth of 35.76% [5]. - The company forecasts revenues of 265 million yuan in 2025, with a net profit of 46 million yuan, and expects continued growth in subsequent years [7][8]. Strategic Initiatives - The company has launched a stock incentive plan to motivate its core team, reflecting confidence in its growth trajectory [5]. - It is actively expanding its product offerings in the medical device sector and humanoid robotics, with ongoing collaborations with various industry players [5][8]. - The company is investing in new manufacturing facilities and establishing a global marketing network to enhance supply chain security and support business growth [8].